Therapeutics (TGTX) 2025 Earnings Outlook for Investors
TG Therapeutics faces a pivotal year as it closes 2025 with a tighter focus on its flagship therapeutics portfolio an...
Comparing ETFs and mutual funds for retirement reveals tax efficiency differences driven by turnover, distributions, and account placement.
28,114 articlesTG Therapeutics faces a pivotal year as it closes 2025 with a tighter focus on its flagship therapeutics portfolio an...
A Needham note argues that Abercrombie & Fitch could surge as stabilizing sales, strong Hollister growth and aggressi...
As Salesforce charts its path to 2027 earnings, investors weigh growth against profitability. This guide breaks down ...
If spacex could make thousands, the IPO narrative could reshape your retirement plan—but only with careful analysis. ...
SpaceX’s blockbuster IPO propelled Elon Musk into a trillion-dollar spotlight. This piece explains what the milestone...
Hedge funds selling tech has stretched into a fourth straight week, led by semiconductors, as investors weigh the sta...
Netflix has opted not to top Paramount's offer, prompting Warner Bros. Discovery to align with Paramount. The move co...
Apple abandons the stalemate of building bigger AI models. In a bold pivot, the company opens iOS 27 to rival assista...
Analysts weigh a bold, unlikely scenario: SpaceX could target a $1 trillion Intel acquisition to lock in silicon for ...
A top strategist warns the AI-driven rally lacks breadth as tech giants lead gains. The trend dubbed tech preventing ...
SpaceX's blockbuster IPO has turned volatile as market conditions cool on AI and space tech bets. The stock has retre...
Smart investors don’t chase every hype. They look for durable advantages, strong cash flow, and clear paths to growth...